Ampio Pharmaceuticals Inc

ASE:AMPE  
1.41
-0.02 (-1.40%)
Products, Regulatory

Ampio Pharmaceuticals Receives Approval To Expand Enrollment Of Its AP-019 Phase Ii Study To India

Published: 06/15/2021 11:01 GMT
Ampio Pharmaceuticals Inc (AMPE) - Ampio Pharmaceuticals Receives Approval to Expand Enrollment of Its Ap-019 Phase Ii Study to India.
Ampio Pharmaceuticals - Phase Ii Study Will Utilize Inhaled Ampion to Treat Those Suffering From Respiratory Distress Due to Covid-19.
Ampio - Due to Ongoing Political Unrest in Israel & Surrounding Region With Reduction in Covid Cases, Made Strategic Decision to Discontinue Ap-019 Study Efforts in Israel.